Accordingly, there is intense interest to develop isoform‐selective HDACi's, notably of HDAC1 and HDAC6 (and HDAC8) (Deng et al. 2023; Ho et al. 2020) HDAC1 is overexpressed in a wide range of solid tumors as well as in several leukemias and lymphomas, including acute lymphoblastic leukemia (ALL), CLL and AML (Deng et al. 2023). Here, HDAC1 is linked to lymphoma.